STOCK TITAN
  1. Home
  2. News
  3. IMAB

I-MAB American Depositary Shares - IMAB STOCK NEWS

Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.

I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.

The company’s pipeline includes several promising candidates:

  • Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
  • Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
  • Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
  • Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
  • Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).

I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.

Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.

For the latest updates and detailed information, visit the official website at I-Mab Biopharma.

News

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
I-Mab (IMAB) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024, focusing on immunotherapies for cancer treatment. The presentation will feature key executives and offer opportunities for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
News

I-Mab Announces Closing of the Divestiture of Business Operations in China

Rhea-AI Summary
I-Mab successfully closes divestiture transaction transferring equity interest in I-Mab Shanghai, with a total consideration of up to US$80 million. The Company extinguishes repurchase obligations of approximately US$183 million and participates in Series C fundraising of the Hangzhou Company for US$19 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News

I-Mab Reports Full Year 2023 Financial Results and Business Update

Rhea-AI Summary
I-Mab reports positive clinical results for uliledlimab and givastomig, plans strategic divestiture in China, and discloses financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
earnings
News

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Rhea-AI Summary
I-Mab (IMAB) has entered into definitive agreements to divest its assets and business operations in China, marking a strategic shift to become a U.S.-based biotech. The agreement provides for a focus on advancing oncology clinical assets, reducing operational costs, and retaining cash in hand, while streamlining the operating model. The company retains ex-China rights to clinical stage assets and aims to remain listed on NASDAQ. The Hangzhou Company will acquire I-Mab drug assets in China, and the Company will participate in the Series C fundraising of the Hangzhou Company for an equity interest subscription of US$19 million in cash. Management and personnel changes include the appointment of an Interim Chairperson and a new Chief Financial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
News

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Rhea-AI Summary
I-Mab, a global biotechnology company, will be participating in two conferences in November 2023: the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. The company's CEO, Dr. Raj Kannan, and CMO, Dr. John Hayslip, will be presenting at both conferences. The conferences will provide opportunities for one-on-one and small group meetings with management. The webcast of the Jefferies conference will be available on I-Mab's IR website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
News

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Rhea-AI Summary
The FDA has granted Breakthrough Therapy Designation for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy (PMN). I-Mab and HI-Bio announced that felzartamab has shown promising data, and the Phase 3 multiple myeloma data is expected in 2024. I-Mab has full development and commercialization rights for felzartamab in Greater China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
none
News

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Rhea-AI Summary
I-Mab (Nasdaq: IMAB) announced that two poster presentations featuring preclinical data on givastomig and TJ-L14B/ABL503 will be reported at the 38th Society for Immunotherapy of Cancer's Annual Meeting. The presentations will focus on the tumor-killing and anti-tumor activity of these bispecific antibody assets in the treatment of gastric cancer and the reinvigoration of exhausted tumor-infiltrating CD8+ T cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
-
News

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Rhea-AI Summary
I-Mab to present updated clinical results of givastomig in advanced solid tumors at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
clinical trial
-
News

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

Rhea-AI Summary
I-Mab announces recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody. Patent rights secured until 2039. Phase 1 study shows promising preliminary efficacy signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
News

I-Mab Announces Upcoming Participation at September Conferences

Rhea-AI Summary
I-Mab announces its participation in two upcoming conferences in September 2023, where management will give presentations and hold meetings. The conferences are the H.C. Wainwright 25th Annual Global Investment Conference and the 2023 Cantor Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
none

FAQ

What is the current stock price of I-MAB American Depositary Shares (IMAB)?

The current stock price of I-MAB American Depositary Shares (IMAB) is $1.07 as of January 22, 2025.

What is the market cap of I-MAB American Depositary Shares (IMAB)?

The market cap of I-MAB American Depositary Shares (IMAB) is approximately 89.7M.

What is I-Mab's core focus?

I-Mab focuses on discovering, developing, and commercializing novel and highly differentiated biologics to treat cancers and autoimmune disorders.

What are some key products in I-Mab's pipeline?

Key products include felzartamab, eftansomatropin, olamkicept, enoblituzumab, and efineptakin.

Where are I-Mab's main operations located?

I-Mab operates primarily from Rockville, Maryland, and San Diego, California.

What recent strategic move has I-Mab made?

I-Mab has divested its Chinese assets and operations to focus more on the U.S. and international markets.

What is felzartamab?

Felzartamab (TJ202) is a CD38 antibody in Phase III trials aimed at treating multiple myeloma and autoimmune diseases.

Who is I-Mab collaborating with on givastomig?

I-Mab is collaborating with Bristol Myers Squibb to study givastomig in combination with nivolumab and chemotherapy for advanced gastric and esophageal cancers.

How does I-Mab fund its operations and research?

I-Mab funds its operations through partnerships, strategic collaborations, and equity investments. Recent strategic divestitures also support its financial health.

What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?

The FDA's Breakthrough Therapy designation for felzartamab recognizes its potential to significantly improve treatment for primary membranous nephropathy and other immune-mediated diseases.

What is I-Mab's approach to drug development?

I-Mab employs Fast-to-Proof-of-Concept and Fast-to-Market strategies, leveraging internal R&D and global partnerships to expedite drug development.

How can investors stay updated on I-Mab's progress?

Investors can stay updated by visiting I-Mab's official website, following their social media channels, and accessing their annual reports and press releases.
Stock IMAB logo
I-MAB American Depositary Shares

Nasdaq:IMAB

IMAB Rankings

#4527 Ranked by Market Cap
N/A Ranked by Dividends

IMAB Stock Data

89.65M
62.31M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville